Stoke Therapeutics, Inc. (STOK) stock
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30178% above fair value
$26.63−0.05 (-0.19%)
Close on Nov 16, 2026Market cap $1.72BP/E –Yield –
Stoke Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Stoke Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $168.57M, up 61.8% year over year. For fiscal 2025 it was $137.92M, up 54.7% from the year before. The highest annual figure on record is $137.92M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.92M | +54.7% |
| FY2024 | Dec 31, 2024 | $89.13M | +8.4% |
| FY2023 | Dec 31, 2023 | $82.23M | +5.6% |
| FY2022 | Dec 31, 2022 | $77.84M | +43.7% |
| FY2021 | Dec 31, 2021 | $54.17M | +68.2% |
| FY2020 | Dec 31, 2020 | $32.20M | +35.5% |
| FY2019 | Dec 31, 2019 | $23.76M | +183.9% |
| FY2018 | Dec 31, 2018 | $8.37M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $49.50M | +91.5% |
| Q1 FY2026 | Mar 31, 2026 | $39.67M | +21.4% |
| Q4 FY2025 | Dec 31, 2025 | $41.70M | +78.0% |
| Q3 FY2025 | Sep 30, 2025 | $37.70M | +69.8% |
| Q2 FY2025 | Jun 30, 2025 | $25.86M | +22.3% |
| Q1 FY2025 | Mar 31, 2025 | $32.68M | +46.1% |
| Q4 FY2024 | Dec 31, 2024 | $23.42M | +7.6% |
| Q3 FY2024 | Sep 30, 2024 | $22.21M | +9.5% |
| Q2 FY2024 | Jun 30, 2024 | $21.14M | +2.8% |
| Q1 FY2024 | Mar 31, 2024 | $22.37M | +13.9% |
| Q4 FY2023 | Dec 31, 2023 | $21.78M | +3.4% |
| Q3 FY2023 | Sep 30, 2023 | $20.27M | +0.8% |
| Q2 FY2023 | Jun 30, 2023 | $20.55M | +11.9% |
| Q1 FY2023 | Mar 31, 2023 | $19.63M | +7.2% |
| Q4 FY2022 | Dec 31, 2022 | $21.06M | +33.3% |
| Q3 FY2022 | Sep 30, 2022 | $20.11M | +40.1% |
| Q2 FY2022 | Jun 30, 2022 | $18.36M | +30.2% |
| Q1 FY2022 | Mar 31, 2022 | $18.31M | +84.7% |
| Q4 FY2021 | Dec 31, 2021 | $15.80M | +77.5% |
| Q3 FY2021 | Sep 30, 2021 | $14.36M | +77.1% |
| Q2 FY2021 | Jun 30, 2021 | $14.10M | +76.9% |
| Q1 FY2021 | Mar 31, 2021 | $9.91M | +37.4% |
| Q4 FY2020 | Dec 31, 2020 | $8.90M | +25.6% |
| Q3 FY2020 | Sep 30, 2020 | $8.11M | +24.4% |
| Q2 FY2020 | Jun 30, 2020 | $7.97M | +32.3% |
| Q1 FY2020 | Mar 31, 2020 | $7.22M | +74.6% |
| Q4 FY2019 | Dec 31, 2019 | $7.09M | +136.0% |
| Q3 FY2019 | Sep 30, 2019 | $6.52M | +192.7% |
| Q2 FY2019 | Jun 30, 2019 | $6.02M | +219.0% |
| Q1 FY2019 | Mar 31, 2019 | $4.13M | – |
| Q4 FY2018 | Dec 31, 2018 | $3.00M | – |
| Q3 FY2018 | Sep 30, 2018 | $2.23M | – |
| Q2 FY2018 | Jun 30, 2018 | $1.89M | – |
See a number that looks wrong?